|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 38/17 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61K 47/48 | (2006.01) | ||
| A61P 37/00 | (2006.01) | ||
| C07K 16/24 | (2006.01) | ||
| C07K 16/28 | (2006.01) |
| (11) | Number of the document | 1983000 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08008814.9 |
| Date of filing the European patent application | 2004-11-16 | |
| (97) | Date of publication of the European application | 2008-10-22 |
| (45) | Date of publication and mention of the grant of the patent | 2015-09-02 |
| (46) | Date of publication of the claims translation | 2015-12-28 |
| (30) | Number | Date | Country code |
| 0327181 | 2003-11-21 | GB | |
| 0417115 | 2004-07-30 | GB |
| (72) |
Christie, Mark Ian, GB
Mead, Richard James, GB
Robinson, Martyn Kim, GB
Rapecki, Stephen Edward, GB
|
| (73) |
UCB Biopharma SPRL,
Allée de la Recherche 60, 1070 Brussels,
BE
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Išsėtinės sklerozės gydymo būdas, inhibuojant IL-17 aktyvumą |
| Method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
| Payment date | Validity (years) | Amount | |
| 2020-10-26 | 17 | 347.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2021-11-16 |